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The gastrointestinal tract is constantly challenged by foreign an-
tigens and commensal bacteria but nonetheless is able to maintain
a state of immunological quiescence. Recent advances have high-
lighted the importance of active suppression by regulatory lym-
phocytes and immunosuppressive cytokines in controlling mucosal
immunity. Failures of these mechanisms contribute to the devel-
opment of inflammatory bowel disease, but how these regulatory
networks are established remains unclear. Here, we demonstrate
key roles for v integrins in regulation of mucosal immunity. We
report that deletion of v in the immune system causes severe
colitis, autoimmunity, and cancer. Mice lacking immune cell v
have fewer regulatory T (Treg) cells in the colon and corresponding
increases in activated T cells and T cell cytokine production, leading
to colitis. Using conditional gene targeting, we demonstrate that
this is specifically attributable to loss of v from myeloid cells.
Furthermore, we show that gut-associated macrophages and den-
dritic cells fail both to remove apoptotic cells efficiently and to
induce Treg cells. Our results identify a vital role for myeloid v
integrins in generating mucosal Treg cells and emphasize the
importance of antigen-presenting cells in establishing immune
tolerance.
immunoregulation  phagocytosis  apoptotic  dendritic cell 
regulatory T cell
Integrins are dimeric cell-surface receptors composed of  and subunits (1). v is the most promiscuous  subunit, associ-
ating with five different  subunits (1, 3, 5, 6, and 8) and
participates in many important cellular processes, including cell
adhesion, migration, survival, and growth factor signaling. v
integrins are expressed in many tissues throughout development,
and v knockout mice die at midgestation from placental
deficiencies or, immediately after birth, with cerebral and intes-
tinal hemorrhage and cleft palate (2). The lethality of v/mice
is attributable mainly to loss of v8, because 8/ mice show
similar placental and neural vasculature abnormalities (3), and
these defects are principally attributable to loss of v8 from
parenchymal tissues supporting blood vessels (4, 5). Knockouts
of most other v-associated  integrins (3, 5, and 6) are
viable and reveal roles for v in repair of tissue injury, inflam-
mation, and immune responses (1, 6–8). v6 and v8 are
expressed in epithelium, where their functions include binding
and activating TGF- (9), and v8 is also expressed by myeloid
cells and T cells (10, 11). v3 and v5 are more widely
expressed and are up-regulated by many cells after tissue injury.
In the immune system, v3 and v5 are expressed by many
different cell types and promote cell adhesion, migration, and
survival. v integrins also mediate the uptake of apoptotic cells
(12–14), a process central to immune regulation and inflamma-
tion resolution (15).
Here, we report that v integrins are central to the normal
regulation of immune responses in the intestine and that deletion
of v in the immune system leads to spontaneous colitis, wasting,
and autoimmunity. Colitis is associated with activated T cells,
high expression of T cell cytokines, and corresponding loss of
tissue-resident regulatory T (Treg) cells. We dissect the contri-
bution of v on different immune cell populations, identifying
myeloid cells [macrophages, dendritic cells (DCs), and/or neu-
trophils] as the critical expressers of v integrins. We further
show that deletion of v leads to impaired removal of apoptotic
cells and failure of mesenteric lymph node (mLN) DCs to
generate Treg cells.
Results
Mice Lacking v Integrins Develop Colitis. Determining the precise
contributions of v integrins to immune functions in vivo has
been limited by the lethal phenotype of v knockout mice, which
die from vascular and developmental defects (2). To circumvent
this problem, we generated a conditional knockout of v
(vflox/f lox mice) [supporting information (SI) Fig. 7], which was
crossed with v-knockout heterozygous mice (v/) and tie2-
CRE transgenic mice (16) to generate v-tie2 and control mice
(vflox/;tie2-cre and vflox/;tie2-cre, respectively). Tie2-
CRE transgenic mice express CRE in endothelial cells and
hemangioblasts, leading to gene deletion specifically in endo-
thelial and hematopoietic cells (17) (Fig. 1 a and b and SI Fig.
7), which was confirmed for both the floxed v allele and v
protein (Fig. 1 c and d).
v-tie2 mice were born at expected frequency and developed
normally with no evidence of defects in angiogenesis or devel-
opment of hematopoietic cells (4) (SI Figs. 8 and 9). However,
from 12 weeks onward, v-tie2 mice lost weight and body
condition compared with controls and died prematurely (median
lifespan of 44 weeks, n  42, compared with 80 weeks for
littermates, n 58) (Fig. 2 a and b). Many v-tie2 mice died after
acute constriction of the intestine (Fig. 2d), suggesting that
defects in intestinal immunity underlie the wasting and death.
Despite these areas of constriction appearing throughout the
intestine, no inflammatory infiltrates were seen in the small
intestine. However, inflammation was seen in the colon and
cecum of all v-tie2 mice from 14 weeks onward, with infiltrates
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of lymphocytes, monocytes, and plasma cells (Fig. 2 c and e–h).
Inflammation was chronic and progressive, leading to ulcers,
acute inflammatory infiltrates, and crypt abscesses by 20 weeks
and extensive epithelial proliferation, regeneration, and adeno-
carcinoma from 40 weeks onward (Fig. 2h and SI Fig. 10).
Inflammation was also found in the peritoneum, in the liver, and,
in 40% of mice, in the nasal cavity and respiratory tract (SI
Fig. 10).
Immune Cell Activation in v-tie2 Mice. Histology of the colon
suggested that the main effector cells mediating inflammation
were T cells, and hence we looked for evidence of T cell
activation. The mLNs and Peyer’s patches of v-tie2 mice were
enlarged compared with controls (Fig. 3a) and contained sig-
nificantly higher proportions of activated (CD62Llow CD44high)
CD4 T cells (Fig. 3B, Table 1, and SI Fig. 11). The spleen and
peripheral lymph nodes (PLNs) also contained higher numbers
of activated CD4 cells in older mice (12 weeks) (SI Fig. 11),
although they did not demonstrate gross enlargement. Expres-
sion of the T cell cytokines IL4 and IFN- was increased both
systemically and in the colon of v-tie2 mice (Fig. 3c and Table
2). Other cytokines were also increased in the colon, including
IL5, IL6, and TNF- but not IL12 and IL23 (SI Fig. 11). Notably,
T cell activation preceded inflammation, with enlargement of
mLNs, T cell activation, and increased expression of IL4 and
IFN- evident even at weaning (3 weeks; Tables 1 and 2),
suggesting colitis arose from early loss of regulation of T cell
responses.
Changes in Treg Cells in v-tie2 Mice. The central importance of
Treg cells in controlling mucosal inflammation is demonstrated
in the many studies showing that, in their absence, effector T
cells rapidly induce colitis and wasting (18). We therefore
examined whether Treg cells were present in v-tie2 mice. Two
principal pathways give rise to Treg cells: ‘‘natural’’ Treg (nTreg)
cells arise in the thymus, are found in lymphoid organs, and
mediate tolerance to self-antigen, whereas ‘‘adaptive’’ Treg
(aTreg) cells arise in the periphery and are thought to be the
main mechanism for regulating responses to tissue-specific or
foreign antigens, such as those derived from commensal bacteria
(19). As determined by CD4 CD25 FoxP3, equivalent num-
bers of Treg cells were found in spleens of controls and v-tie2
mice, whereas the mLN of v-tie2 mice contained increased
proportions of Tregs as compared with controls (Fig. 3d). These
cells are likely to be predominantly natural Tregs and appear to
be generated in the absence of v. In contrast with the results for
spleen and mLN, the colons of v-tie2 mice had significantly
decreased numbers (50% reduction) of Treg cells compared with
Fig. 1. Deletion of v integrins in endothelial and hematopoietic cells in
v-tie2 mice. (a and b) Small intestine from tie2-CRE transgenic mice crossed
to LacZ reporter mice, stained for LacZ activity. (a) CRE-mediated deletion in
blood vessels and immune organs, indicated by an arrowhead and arrow,
respectively. (b) Sections of stained tissue show CRE-mediated deletion in
endothelial cells in vessels from control and reportermice (Upper) and a single
blood vessel from reporter mice at higher magnification (Lower). (c) PCR
across exon 4 of v gene in DNA from sorted lung endothelial cells (CD31
cells) or splenocytes from mice carrying one floxed and one nonfloxed allele
for v show that the floxed allele is lost when mice also carry the tie2-CRE
transgene. (d) FACS analysis of macrophages and total splenocytes from
control (v flox/; tie2-CRE) or v-tie2 mice stained for surface expression of
v. Red lines show staining with isotype control antibody, and blue-filled
histograms show staining for v.
Fig. 2. v-tie2 mice develop colitis. (a–c) Weight (a), survival (b), and colitis
score (c) ofv-tie2 (bluebars/blue line) and littermate control (openbars/black
line) mice. Weight and colitis scores are expressed as mean  SEM (n  3–13
mice per group; males only used for weight; similar results seen for females).
*, P 0.01. (d) Acute intestinal obstruction inv-tie2mouse (20weeks of age).
Arrows show points of constriction in small intestine. (e) Cecum and colon
from v-tie2 mice (40 weeks) are enlarged compared with those from control
mice. The cecum is inflamed (arrows), and the colon is thickened (arrowheads).
( f) Colons of 20-week-old v-tie2 mice have thickened mucosal and submu-
cosal layers with transmural inflammation. Infiltrates are predominantly lym-
phocytes and monocytes. (g and h) Ulcer (#) (g) and tumor (*) (h) in colons of
40-week-old v-tie2 mice.
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controls (Fig. 3d). These Treg cells are probably aTreg cells,
suggesting that failure to generate these cells leads to loss of
mucosal tolerance in v-tie2 mice.
Colitis Is Caused by Loss of v from Myeloid Cells. The above data
indicate that T cells are the main effectors of inflammation in
v-tie2 mice and suggest that this may be attributable to loss of
colon Tregs. However, because Tie2-CRE causes deletion in
both endothelial and hematopoietic cells (Fig. 1), these changes
in T cells could either be attributable to direct effects of loss of
v from T cells or indirect effects after loss of v from other cell
types. We therefore carried out a series of experiments to test
directly the importance of v on T cells and other immune cells.
Transplant of an v-deficient immune system to lethally irradi-
ated control mice resulted in weight loss and colitis (Fig. 4 a and
b), and, conversely, reconstitution of old (24-week-old) v-tie2
mice with control bone marrow reversed ongoing inflammation
with restoration of normal colon histology (Fig. 4 a and b).
Therefore, inflammation and colonic damage did not arise from
defects in intestinal development or from loss of v from
endothelial cells, but were directly attributable to deletion of v
in the immune system.
We then generated four additional v-f lox CRE mouse lines
to analyze contributions of v on immune cell subpopulations.
Mice lacking v on T cells, B cells, or both T and B cells did not
develop colitis despite efficient deletion of v (Fig. 4 c and d and
SI Fig. 12). In contrast, mice lacking v on macrophages,
neutrophils, andDCs [v-LysMmice (20)] (SI Fig. 11) developed
colitis closely resembling that from v-tie2 mice, with similar
histology and proinflammatory cytokine expression (Fig. 4 c–f ).
The incidence and severity of disease were lower in these mice
than in v-tie2 mice of the same age (30% severe colitis in
v-LysM at 40 weeks compared with 100% in v-tie2), probably
as a consequence of incomplete gene deletion (20) (50–80%
gene deletion in v-LysM mice compared with 100% in v-tie2)
(SI Fig. 12). Taken together, these data show that inflammation
does not arise from loss of v on adaptive immune cells but
instead indicate an important role for v on myeloid cells in
immune regulation.
Impaired Function of mLN DCs in v-tie2 Mice. The dependence of
colitis on deletion of v from myeloid cells raised the possibility
that the loss of colon Treg cells was attributable to defects in
DCs. We therefore tested the ability of v-deficient DCs to
generate aTreg cells. Culture of bone marrow DCs with CD4
CD25 T cells generated 5% Treg cells regardless of v
expression by the DCs (Fig. 5a). However DCs from mLNs of
v-tie2 mice generated fewer (1% compared with 4–5%) CD4
CD25 FoxP3 T cells than DCs from control mice (Fig. 5a).
These results show that mucosal DCs but not bone marrow-
derived DCs from v-tie2 mice are impaired in their ability to
generate Treg cells. It is recognized that certainmLNDC subsets
induce differentiation of T cells into Treg cells and that a specific
population, marked by expression of CD103 (E7 integrin), is
implicated in imprinting gut-homing (21). CD11chigh CD103
DCs were reduced in mLNs of v-tie2 mice (Fig. 5b), providing
a potential explanation for the reduction in intestinal Treg cells.
Impaired Removal of Apoptotic Cells in v-tie2 Mice. Both v3 and
v5 on macrophages and DCs have been implicated in the
removal of apoptotic cells (11–13), a process known to contribute
to regulation of inflammation and immune tolerance (14).
Furthermore, phagocytosis of apoptotic cells reprograms mac-
rophages and DCs to a tolerogenic phenotype, in part through
TGF-, and is associated with the production of Tregs (22).
Macrophages derived from v-tie2 mice had impaired phago-
cytosis of apoptotic cells, comparable with that seen when v
blocking antibodies or ligand-mimetic peptide [arginine-glycine-
aspartic acid (RGD)] were used (Fig. 6a). This was not attrib-
utable to defective differentiation of cells in the absence of v,
because deletion of v from mature macrophages also resulted
in inhibition of phagocytosis (Fig. 6b and SI Fig. 13). Further-
Table 2. Proinflammatory cytokine expression in colon of v-tie2












Control 26  4.7 26  9.9 2.1  0.58 1.3  1.0
 v-tie2 326  122 518  236 268  109 228  105
Gene expression is relative to GAPDH,  103. P values are from Student’s
t test.
Fig. 3. Immune cell activation inv-tie2mice. (a) Total cell numbers isolated fromperitoneal cavity (PerC), peripheral lymphnodes (pLN) andmLN, Peyer’s patch
(PP), and spleenof 12-week-oldv-tie2 and controlmice. (b) FACS analysis of spleen cells from12-week-old control andv-tie2mice, gatedonCD4 T cells, shows
higher proportions of activated (CD44high L-selectinlow) CD4 cells in v-tie2mice. (c) Circulating cytokines from serumof v-tie2 or controlmice (aged 12weeks).
(d) Treg cells from indicated tissues from 8-week-old v-tie2 and control mice. Data are expressed as percentage of CD4 cells that are CD25 FoxP3. FACS data
are representative of colon lymphocytes, gated on CD4 cells. In all graphs, data are means  SEM for at least three mice per group. *, P  0.05.
Table 1. Comparison of T cell activation in mLN v-tie2 mice
before (3 weeks) and after (12 weeks) onset of histologically
evident colitis
Mice









Control 7.1  0.23 8.6  1.6 11  1.3 15  0.81
v-tie2 15  1.1 34.2  6.7 20  0.81 31.7  0.40
T cell activation was assessed by CD44 and L-selectin staining. P values are
from Student’s t test.









more, macrophages lacking v were no longer sensitive to the
inhibitory effects of RGD peptides (Fig. 6b). Similar phagocytic
defects were seen in DCs derived from v-tie2 mice (Fig. 6c). To
determine whether deletion of v affected phagocytosis in vivo,
we carried out two further experiments. First, apoptotic cells
were injected into the peritoneal cavity, and their internalization
by macrophages were measured. Reduced phagocytosis was seen
in both v-tie2 and v-LysMmice (Fig. 6d). Second, to assess the
rate of removal of apoptotic cells from the intestine, we mea-
sured the number of uncleared TUNEL cells in the colons of
control and v-tie2 mice at 6 weeks of age (before the onset of
colitis). Twice as many apoptotic cells were seen in v-tie2 mice,
consistent with reduced phagocytosis and apoptotic cell removal
(Fig. 6 e–f ). A well recognized consequence of persistent apo-
ptotic cells is the generation of autoantigens that, in turn, drive
autoantibody production (23). We therefore determined
whether mice lacking v had increased levels of autoantibodies.
Serum from both v-tie2 and v-LysM mice contained high
levels of autoantibodies, including antibodies to tropomyosin, an
autoantigen associated with colitis in humans (24), and antibod-
ies to prominent components of dying cells, such as phosphati-
dylserine, dsDNA, and anti-nuclear antibodies (Fig. 6 g–i).
Discussion
In summary, we have shown that v integrins are central to
intestinal immune regulation and that deletion of v leads to
colitis, autoimmunity, and cancer, thus establishing a mouse
model for inflammatory bowel disease. The maintenance of
mucosal immune homeostasis relies on the sampling of intestinal
antigens by DCs and the subsequent production of aTreg cells
that home to the intestine and regulate immune responses.
Colitis in v-tie2 mice is likely to be caused by loss of these colon
aTreg cells and corresponding increases in activated T cells and
T cell cytokine production. This phenotype is attributable to loss
of v from macrophages and DCs, which reduces phagocytosis
of apoptotic cells and inhibits the generation of mucosal aTreg
cells.
The generation and function of aTreg cells requires TGF-
signaling in and between T cells, and mice lacking TGF- or
TGF- signaling components specifically in T cells have pheno-
types resembling those of v-tie2 mice (25, 26). It is pertinent
that v, when dimerized with 6 and 8, binds and activates
TGF- (9). Loss of v-mediated TGF- activationmay therefore
contribute to the v-tie2 phenotype, and we propose that
DC-expressed v integrins locally activate TGF-, which acts in
a paracrine fashion to initiate Treg differentiation in T cells.
Furthermore, our data suggest that TGF- production by T cells
is insufficient to regulate immune responses in the absence of
TGF- activation by antigen-presenting cells, providing a mech-
anism by which antigen specificity is retained in aTreg cells. The
DCs that inhabit mucosal tissues appear particularly sensitive to
the loss of v integrins because bone marrow-derived DCs
generate Tregs normally in the absence of v. TGF- is present
at high levels in the intestine, and it is likely that v also
contributes to TGF- signaling during DC maturation, because
TGF- conditions DCs to generate aTreg cells. Furthermore,
fewer mLN DCs from v-tie2 mice express CD103 (E inte-
grin), which is stimulated by TGF-. We propose that absence
of these DCs reflects, in part, failure of macrophages and DCs
in the intestine to activate TGF-.
Colitis is not seen in mice lacking 3, 5, or 6 integrins or in
hematopoietic 1 knockouts (27), heavily implicating 8 in
control of mucosal immunity. Recent complementary condi-
Fig. 4. Loss of v from myeloid cells (but not lymphocytes) causes colitis. (a
and b) Representative histology of colon (a), weight (b), and colitis score (b) of
mice after bone marrow transplantation between 3-month-old v-tie2 (KO)
and control (WT) mice. Colitis was assessed a further 3 months after bone
marrow transplantation. Note that transplantation of v-deficient bonemar-
row (KO 3 WT) leads to colitis, whereas transplantation of control bone
marrow is sufficient to reverse ongoing disease (WT3 KO). (c and d) Repre-
sentative histology of colon (c) and colitis score (d) from indicated v-
conditional knockout mice at 40–50 weeks of age. Deletion of v from T cells
(v-lck) or from B cells (v-CD19) does not lead to colitis, whereas deletion of
v from myeloid cells (v-LysM) does. (e) Detail of colon (Upper) and mesen-
tery (Lower) from 70 week-old v-LysM mouse. Note ulceration in colon (*)
and inflammation in mesentery. ( f) Serum cytokine levels in 20-week-old
v-LysMmice. All graphs are mean SEM (n 4 mice per group). *, P 0.05.
Fig. 5. DCs from mLN of v-tie2 mice have reduced ability to generate Treg
cells. (a) Proportion of Treg cells generated from coculture of CD4 CD25 T
cells with DCs purified frommLN or grown from bonemarrow (bm) of control
and v-tie2 mice. (b) Proportion of DC subpopulations in mLN of 10-week-old
control andv-tie2mice, expressedaspercentageofCD11chigh cells. All graphs
are mean  SEM (n  3). *, P  0.05.
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tional knockout studies confirm this, showing that loss of v8
integrins from DCs but not from T cells also causes colitis (11).
However, the phenotype of these mice is less severe than that
seen in v-tie2 mice, suggesting that loss of other v integrins
contributes to the severity of colitis. v3 and v5 have been
implicated in the removal of apoptotic cells by macrophages and
DCs, and v-deficient mice have impaired phagocytosis of
apoptotic cells, leading to persistence of dying cells in the colon.
Apoptotic epithelial cells are thought to provide an important
source of intestinal self-antigen, and DCs that exit the intestine
bearing apoptotic cells express low levels of costimulatory
molecules and are poor stimulators of T cell responses (28). Such
‘‘functionally immature’’ DCs have been shown to preferentially
induce Treg differentiation when compared with classically
activated DCs, and similar DCs can be induced in vitro by culture
with apoptotic cells (29). Phagocytosis of apoptotic cells may
therefore provide intestinal DCs with both antigen and the
appropriate conditioning to generate Tregs. Impaired phagocy-
tosis would lead to fewer DCs bearing apoptotic cells in the
lymph nodes and potentially fewer Treg cells. The importance of
this process in maintaining immune tolerance is demonstrated by
genetic deletion of key components of the apoptotic cell-
recognition machinery, which leads to persistent apoptotic cells,
chronic inflammation, and development of autoimmune disease
resembling systemic lupus erythematosus (15). These include
mice lacking the serum protein MFGE8/Lactadherin, which
mediates apoptotic cell removal through v integrins, implicat-
ing v-dependent removal of apoptotic cells in the induction of
immune tolerance (30). Hence, although phagocytosis defects
may not be sufficient to induce the colitis seen in v-tie2 and
v-LysMmice, they are likely to contribute to autoimmunity and
inflammation. Intriguingly, many of the effects of apoptotic cell
uptake have been attributed to the release of TGF-, and it is
tempting to speculate that uptake of apoptotic cells, synthesis of
active TGF-, and generation of Tregs are causally linked (31).
In support of this possibility, systemic administration of large
numbers of apoptotic cells promotes Treg expansion through
TGF- production (22), a process critically dependent on both
macrophages and DCs.
We therefore propose a model of mucosal tolerance in which
v integrins have a dual role: v3 and v5 would mediate
uptake of apoptotic cells by macrophages and DCs, thus pro-
viding self antigen and modifying the extent of inflammation,
and v8 would generate Treg cells through local activation of
TGF- and conditioning of DCs (SI Fig. 14). The results
presented here and our proposed model emphasize the vital role
of antigen-presenting cells in regulation of inflammatory re-
sponses and maintenance of immune tolerance. Furthermore,
these studies demonstrate the pleiotrophic role of v integrins in
the regulation of mucosal immune responses and provide in-
sights into mechanisms that control inflammatory bowel disease.
Methods
Mice. Generation of mice is described in SI Text. All mice used
in the study were of mixed 129:C57BL/6:FVB background and
Fig. 6. v integrins contribute to phagocytosis of apoptotic cells. (a) Phagocytosis of apoptotic cells (mouse thymocytes) by macrophages from control (con)
or v-tie2 mice (ko) or macrophages incubated with antibodies to v integrins (v), control Ig (Ig), RGD-containing peptides (RGD), or control peptide (RAD)
(mean percentage phagocytic cells relative to untreated controls SEM; n 3). (b) Phagocytosis of apoptotic cells (human neutrophils) by macrophages from
control or vflox/flox mice, untreated, or infectedwith adenovirus expressing CRE recombinase (MOI 100) (mean percentage phagocytic cells relative to untreated
controls  SEM; n  3). (c) Phagocytosis of apoptotic cells (mouse thymocytes) by DCs derived from bone marrow of control or v-tie2 mice (mean percentage
phagocytic cells SEM; n 3). (d) Phagocytosis of apoptotic cells (mouse thymocytes) instilled into the peritoneal cavity of control, v-tie2, and v-LysM mice.
Data are percentage of recovered macrophages (F4/80 cells) that had internalized apoptotic cells, expressed relative to control mice (mean  SEM; n  5).
Phagocytosis was assessed by microscopy (a and b) or FACS (c and d). (e) Apoptotic cells (TUNEL cells) in colonic mucosae of precolitic 6-week-old v-tie2 and
controlmice. Data are from analysis of two colon cross-sections permouse and3mice per group (mean SEM). Shown are representative regions from control
andv-tie2mice. ( f) Autoantibodies in serumfromcontrol andv-tie2mice. (g) Antinuclear antibody (ANA) titers in serumfrom45-week-old control andv-tie2.
Serum from autoimmune MRL-mp mice is included as a positive control. (h) Anti-dsDNA autoantibodies in serum of 70-week-old v-LysMmice. In all graphs, *,
P  0.05; **, P  0.01 (Student’s t test for phagocytosis data, Mann–Whitney test for autoantibody titers).









were housed under specific pathogen free conditions at Massa-
chusetts Institute of Technology. Animal experiments were
performed under appropriate licenses within local and national
guidelines for animal care.
Analysis of Colitis. Representative longitudinal and cross-sections
of large intestine were stained with hematoxylin and eosin and
graded by using a scheme based on that described by Powrie and
colleagues (32), as follows: 0  normal; 1  mild epithelial
hyperplasia, mild mucosal inflammation; 2  moderate hyper-
plasia, mucin depletion, moderate inflammation; 3  severe
hyperplasia, transmural inflammation, ulceration. The highest
score seen in sections from the length of the colon and cecumwas
reported for each mouse. All scoring was on coded samples and
independently confirmed by two pathologists (M.B. and R.T.B.).
Immune Analysis. Cell preparation and staining are described in
SI Text. Serum cytokines were measured by in vivo cytokine
capture assay. All autoantibody titers were determined by
ELISA (SI Text) except antinuclear antibodies, which were from
staining of HEP-G2 cells.
Treg Cell Generation. CD11c DCs were sorted from mLN or
spleen by using CD11c microbeads (Miltenyi Biotech, Auburn,
CA) and were routinely85%CD11c cells after sorting. CD4
CD25 T cells were sorted from spleen suspensions by enrich-
ment of CD4 cells followed by depletion of CD25 cells, using
MACs microbeads (Miltenyi Biotech). A total of 105 T cells were
cultured with 2–5  104 DCs in the presence of 0.5 g/ml
anti-CD3 antibody for 3 days, and the proportion of CD4
CD25 FoxP3 cells was measured by FACS.
Phagocytosis Assays. Bone marrow-derived macrophage and DC
culture, apoptotic cell generation, and phagocytosis assays are
described in refs. 29 and 33. For v blockade, anti-v (H9–2B8),
control Ig (E36–239) (50 g/ml; both BD Biosciences Phar-
Mingen, San Diego, CA), glycine-RGD-serine, or glycine-RAD-
serine (0.5 mg/ml; both Calbiochem, San Diego, CA) were
incubated with macrophages for 20–30 min before and through-
out phagocytosis assays. For in vivo phagocytosis, 107 fluores-
cently labeled apoptotic thymocytes were injected into the
peritoneal cavity, and phagocytosis were assayed after 20 min by
FACS of F4/80-stained lavages.
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